Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.

NCT00740584 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections
HSV-2 Genital Herpes

Interventions

DRUG: 3% SPL7013 Gel (VivaGel)

Sponsor

Starpharma Pty Ltd

Collaborators

[object Object]